Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients
Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults w...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2010/856542 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561825757003776 |
|---|---|
| author | Emily L. Heil Mary L. Townsend Kenneth Shipp Amy Clarke Melissa D. Johnson |
| author_facet | Emily L. Heil Mary L. Townsend Kenneth Shipp Amy Clarke Melissa D. Johnson |
| author_sort | Emily L. Heil |
| collection | DOAJ |
| description | Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results. Fifty-six of the 544 patients identified met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients). Severe hepatotoxicity occurred with efavirenz (𝑁=2), nevirapine (𝑁=1), indinavir (𝑁=1), nelfinavir (𝑁=1), and saquinavir/ritonavir (𝑁=1). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen. |
| format | Article |
| id | doaj-art-30aee516636742d99cadb5bb6c85ffb5 |
| institution | Kabale University |
| issn | 2090-1240 2090-1259 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | AIDS Research and Treatment |
| spelling | doaj-art-30aee516636742d99cadb5bb6c85ffb52025-02-03T01:24:05ZengWileyAIDS Research and Treatment2090-12402090-12592010-01-01201010.1155/2010/856542856542Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected PatientsEmily L. Heil0Mary L. Townsend1Kenneth Shipp2Amy Clarke3Melissa D. Johnson4Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USACollege of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, USADepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USAPharmacy Department, Durham Veterans Affairs Medical Center, Durham, NC 27705, USACollege of Pharmacy & Health Sciences, Campbell University, Buies Creek, NC 27506, USAIntroduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results. Fifty-six of the 544 patients identified met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients). Severe hepatotoxicity occurred with efavirenz (𝑁=2), nevirapine (𝑁=1), indinavir (𝑁=1), nelfinavir (𝑁=1), and saquinavir/ritonavir (𝑁=1). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen.http://dx.doi.org/10.1155/2010/856542 |
| spellingShingle | Emily L. Heil Mary L. Townsend Kenneth Shipp Amy Clarke Melissa D. Johnson Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients AIDS Research and Treatment |
| title | Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients |
| title_full | Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients |
| title_fullStr | Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients |
| title_full_unstemmed | Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients |
| title_short | Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients |
| title_sort | incidence of severe hepatotoxicity related to antiretroviral therapy in hiv hcv coinfected patients |
| url | http://dx.doi.org/10.1155/2010/856542 |
| work_keys_str_mv | AT emilylheil incidenceofseverehepatotoxicityrelatedtoantiretroviraltherapyinhivhcvcoinfectedpatients AT maryltownsend incidenceofseverehepatotoxicityrelatedtoantiretroviraltherapyinhivhcvcoinfectedpatients AT kennethshipp incidenceofseverehepatotoxicityrelatedtoantiretroviraltherapyinhivhcvcoinfectedpatients AT amyclarke incidenceofseverehepatotoxicityrelatedtoantiretroviraltherapyinhivhcvcoinfectedpatients AT melissadjohnson incidenceofseverehepatotoxicityrelatedtoantiretroviraltherapyinhivhcvcoinfectedpatients |